Celldex Therapeutics, Inc.
CLDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1,351,077 | $1,204,851 | $1,676,740 |
| - Cash | $36,037 | $23,044 | $17,136 | $28,356 |
| + Debt | $1,068 | $3,031 | $3,428 | $3,813 |
| Enterprise Value | – | $1,331,064 | $1,191,143 | $1,652,197 |
| Revenue | $0 | $730 | $695 | $1,175 |
| % Growth | -100% | 5% | -40.9% | – |
| Gross Profit | $0 | $730 | $695 | $356 |
| % Margin | – | 100% | 100% | 30.3% |
| EBITDA | -$66,220 | -$62,984 | -$61,872 | -$55,208 |
| % Margin | – | -8,627.9% | -8,902.4% | -4,698.6% |
| Net Income | -$67,044 | -$56,600 | -$53,796 | -$47,092 |
| % Margin | – | -7,753.4% | -7,740.4% | -4,007.8% |
| EPS Diluted | -1.01 | -0.85 | -0.81 | -0.71 |
| % Growth | -18.8% | -4.9% | -14.1% | – |
| Operating Cash Flow | -$48,628 | -$44,005 | -$54,372 | -$32,476 |
| Capital Expenditures | -$440 | -$728 | -$265 | -$756 |
| Free Cash Flow | -$49,068 | -$44,733 | -$54,637 | -$33,232 |